The Expanding Therapeutic Presence of Nanomedicine ZPH
Examples of broad-spectrum anti-cancer therapeutics across multiple oncology settings, including breast cancer:
1. Keytruda (Pembrolizumab)
• Manufacturer: Merck & Co.
• Annual Sales Peak: $14.38 billion in 2022
• Mechanism of Action: PD-1 inhibitor (immune checkpoint inhibitor)
• Cancers Treated: Breast cancer, non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, classical Hodgkin lymphoma, urothelial carcinoma, gastric cancer, and more.
2. Opdivo (Nivolumab)
• Manufacturer: BristolMyersSquibb
• Annual Sales Peak: $8.4 billion in 2022
• Mechanism of Action: PD-1 inhibitor (immune checkpoint inhibitor)
• Cancers Treated: Breast cancer, NSCLC, melanoma, renal cell carcinoma, classical Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, and more.
3. Herceptin (Trastuzumab)
• Manufacturer: Genentech/#Roche
• Annual Sales Peak: $7.4 billion in 2018
• Mechanism of Action: HER2 receptor antagonist
• Cancers Treated: HER2-positive breast cancer, HER2-positive gastric cancer.
4. Avastin (Bevacizumab)
• Manufacturer: Genentech/Roche
• Annual Sales Peak: $7.1 billion in 2018
• Mechanism of Action: VEGF inhibitor (angiogenesis inhibitor)
• Cancers Treated: Breast cancer, colorectal cancer, NSCLC, glioblastoma, renal cell carcinoma, ovarian cancer, and cervical cancer.
5. Imfinzi (Durvalumab)
• Manufacturer: AstraZeneca
• Annual Sales Peak: $2.0 billion in 2022
• Mechanism of Action: PD-L1 inhibitor (immune checkpoint inhibitor)
• Cancers Treated: Breast cancer, NSCLC, urothelial carcinoma, and small cell lung cancer (SCLC).
6. Lenvima (Lenvatinib)
• Manufacturer: Eisai
• Annual Sales Peak: $1.5 billion in 2020
• Mechanism of Action: Multiple receptor tyrosine kinase inhibitor
• Cancers Treated: Breast cancer, hepatocellular carcinoma, renal cell carcinoma, thyroid cancer, and endometrial cancer.
